NEW YORK, Aug. 26 -- Drugmaker GlaxoSmithKline agreed Thursday to settle charges that it hid and misrepresented unfavorable data about the effectiveness and safety of its top-selling anti-depressant Paxil for children and adolescents, agreeing to post all clinical trial data on its drugs by the end of 2005.